MA46514A - Dérivés de 6- (1h-pyrazol-1-yl) pyrimidin-4-amine substitués et leurs utilisations - Google Patents
Dérivés de 6- (1h-pyrazol-1-yl) pyrimidin-4-amine substitués et leurs utilisationsInfo
- Publication number
- MA46514A MA46514A MA046514A MA46514A MA46514A MA 46514 A MA46514 A MA 46514A MA 046514 A MA046514 A MA 046514A MA 46514 A MA46514 A MA 46514A MA 46514 A MA46514 A MA 46514A
- Authority
- MA
- Morocco
- Prior art keywords
- pyrazol
- pyrimidin
- amine derivatives
- amine
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16193953 | 2016-10-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46514A true MA46514A (fr) | 2019-08-21 |
Family
ID=57136772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046514A MA46514A (fr) | 2016-10-14 | 2017-10-09 | Dérivés de 6- (1h-pyrazol-1-yl) pyrimidin-4-amine substitués et leurs utilisations |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US11208400B2 (fr) |
| EP (1) | EP3526212B1 (fr) |
| JP (1) | JP2019532961A (fr) |
| KR (1) | KR20190065402A (fr) |
| CN (1) | CN110191884A (fr) |
| AR (1) | AR109947A1 (fr) |
| AU (1) | AU2017341324A1 (fr) |
| BR (1) | BR112019007496A2 (fr) |
| CA (1) | CA3040166A1 (fr) |
| CL (1) | CL2019001004A1 (fr) |
| CO (1) | CO2019003761A2 (fr) |
| CR (1) | CR20190192A (fr) |
| CU (1) | CU24518B1 (fr) |
| DO (1) | DOP2019000099A (fr) |
| EA (1) | EA201990947A1 (fr) |
| EC (1) | ECSP19026563A (fr) |
| GE (2) | GEP20217269B (fr) |
| IL (1) | IL265923A (fr) |
| JO (1) | JOP20190080A1 (fr) |
| MA (1) | MA46514A (fr) |
| MX (1) | MX381873B (fr) |
| PE (1) | PE20191549A1 (fr) |
| PH (1) | PH12019500808A1 (fr) |
| SG (1) | SG11201903305XA (fr) |
| TN (1) | TN2019000114A1 (fr) |
| TW (1) | TW201825477A (fr) |
| UY (1) | UY37444A (fr) |
| WO (1) | WO2018069222A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110734428A (zh) * | 2019-10-24 | 2020-01-31 | 嘉兴特科罗生物科技有限公司 | 一种小分子化合物 |
| CN115403524A (zh) * | 2021-05-26 | 2022-11-29 | 浙江省化工研究院有限公司 | 3-氟代吡唑羧酸酯、3-氟代烷基-1-取代吡唑-4-羧酸的制备方法 |
| AU2023346584A1 (en) | 2022-09-19 | 2025-03-27 | Basf Se | Azole pesticidal compounds |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966781A (en) | 1970-12-17 | 1976-06-29 | Merck Sharp & Dohme (I.A.) Corporation | Deuteration of functional group-containing hydrocarbons |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| CA2371910A1 (fr) | 1999-01-21 | 2000-07-27 | Brian E. Peerce | Inhibiteurs de cotransport de na/phosphate de membrane apicale intestinale |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| US7119120B2 (en) | 2001-12-26 | 2006-10-10 | Genzyme Corporation | Phosphate transport inhibitors |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| DE102008020113A1 (de) * | 2008-04-23 | 2009-10-29 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dihydropyrazolone und ihre Verwendung |
| ATE519759T1 (de) | 2004-12-30 | 2011-08-15 | Exelixis Inc | Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren |
| CA2684240A1 (fr) * | 2007-04-16 | 2008-10-30 | Serenex, Inc. | Derives de tetrahydroindole et de tetrahydroindazole |
| JP2008296610A (ja) | 2007-05-29 | 2008-12-11 | Toyota Motor Corp | 車両用動力伝達装置の制御装置 |
| TWI526687B (zh) * | 2008-04-29 | 2016-03-21 | 諾華公司 | 生物標記 |
| SG172352A1 (en) | 2008-12-23 | 2011-07-28 | Abbott Lab | Anti-viral compounds |
| DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| UA109650C2 (xx) | 2010-02-27 | 2015-09-25 | Біс-арилзв'язані арилтриазолони та їх застосування | |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| EP2588465B1 (fr) * | 2010-06-30 | 2017-01-25 | Ironwood Pharmaceuticals, Inc. | Stimulateurs de sgc |
| WO2012006474A2 (fr) | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Composés et procédés pour l'inhibition du transport de phosphate |
| JP5827328B2 (ja) | 2010-07-07 | 2015-12-02 | アーデリクス，インコーポレーテッド | リン酸輸送を阻害する化合物及び方法 |
| WO2012006473A1 (fr) | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Composés et procédés pour l'inhibition du transport de phosphate |
| WO2012054110A2 (fr) | 2010-07-07 | 2012-04-26 | Ardelyx, Inc. | Composés et procédés permettant d'inhiber le transport du phosphate |
| EP2591354B1 (fr) * | 2010-07-07 | 2016-09-07 | Ardelyx, Inc. | Composés et procédés pour l'inhibition du transport de phosphate |
| EA201390060A1 (ru) | 2010-07-09 | 2013-07-30 | Байер Интеллектуэль Проперти Гмбх | Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| US8791162B2 (en) | 2011-02-14 | 2014-07-29 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| KR101941048B1 (ko) | 2011-10-27 | 2019-01-22 | 아스텔라스세이야쿠 가부시키가이샤 | 아미노 알킬 치환 n-티에닐벤즈아미드 유도체 |
| WO2013082756A1 (fr) | 2011-12-06 | 2013-06-13 | Leo Pharma A/S | Inhibiteurs de transport de phosphate ii |
| US10150742B2 (en) | 2013-03-15 | 2018-12-11 | President And Fellows Of Harvard College | Substituted heterocyclic compounds for treating or preventing viral infections |
| WO2014181287A1 (fr) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Composés hétérocyclyliques et leurs utilisations |
| TWI582083B (zh) * | 2014-10-07 | 2017-05-11 | 美國禮來大藥廠 | 胺基吡啶基氧基吡唑化合物 |
| SI3215498T1 (sl) | 2014-11-03 | 2018-11-30 | Bayer Pharma Aktiengesellschaft | Hidroksialkil-substituirani derivati feniltriazola in njihove uporabe |
| CN105631664A (zh) | 2014-11-26 | 2016-06-01 | 华为终端（东莞）有限公司 | 一种非接触支付方法、装置及系统 |
| WO2016105525A2 (fr) * | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Nouvelles pyrimidines en tant qu'inhibiteurs d'egfr et procédés de traitement de troubles |
| ES2886122T3 (es) | 2016-10-14 | 2021-12-16 | Inst Pasteur De Montevideo | Moduladores antinflamatorios y metabólicos pluripotentes para el tratamiento de afecciones relacionadas con la inflamación |
| US10934273B2 (en) | 2016-10-14 | 2021-03-02 | Novartis Ag | Crystalline forms of 4-(2-((1R,2R)-2-hydroxycyclohexylamino)benzothiazol-6-yloxy)-N-methylpicolinamide |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
-
2017
- 2017-06-16 JO JOP/2019/0080A patent/JOP20190080A1/ar unknown
- 2017-10-09 CR CR20190192A patent/CR20190192A/es unknown
- 2017-10-09 SG SG11201903305XA patent/SG11201903305XA/en unknown
- 2017-10-09 CN CN201780074126.5A patent/CN110191884A/zh active Pending
- 2017-10-09 KR KR1020197013647A patent/KR20190065402A/ko not_active Ceased
- 2017-10-09 MX MX2019004347A patent/MX381873B/es unknown
- 2017-10-09 CA CA3040166A patent/CA3040166A1/fr active Pending
- 2017-10-09 EP EP17780751.8A patent/EP3526212B1/fr active Active
- 2017-10-09 CU CU2019000035A patent/CU24518B1/es unknown
- 2017-10-09 PE PE2019000822A patent/PE20191549A1/es unknown
- 2017-10-09 GE GEAP201715076A patent/GEP20217269B/en unknown
- 2017-10-09 TN TNP/2019/000114A patent/TN2019000114A1/en unknown
- 2017-10-09 WO PCT/EP2017/075630 patent/WO2018069222A1/fr not_active Ceased
- 2017-10-09 AU AU2017341324A patent/AU2017341324A1/en not_active Abandoned
- 2017-10-09 US US16/341,410 patent/US11208400B2/en not_active Expired - Fee Related
- 2017-10-09 GE GEAP202115076A patent/GEAP202115076A/en unknown
- 2017-10-09 EA EA201990947A patent/EA201990947A1/ru unknown
- 2017-10-09 JP JP2019519748A patent/JP2019532961A/ja active Pending
- 2017-10-09 MA MA046514A patent/MA46514A/fr unknown
- 2017-10-09 BR BR112019007496A patent/BR112019007496A2/pt not_active Application Discontinuation
- 2017-10-12 TW TW106134859A patent/TW201825477A/zh unknown
- 2017-10-13 AR ARP170102862A patent/AR109947A1/es unknown
- 2017-10-13 UY UY0001037444A patent/UY37444A/es not_active Application Discontinuation
-
2019
- 2019-04-08 IL IL265923A patent/IL265923A/en unknown
- 2019-04-12 EC ECSENADI201926563A patent/ECSP19026563A/es unknown
- 2019-04-12 CL CL2019001004A patent/CL2019001004A1/es unknown
- 2019-04-12 CO CONC2019/0003761A patent/CO2019003761A2/es unknown
- 2019-04-12 PH PH12019500808A patent/PH12019500808A1/en unknown
- 2019-04-12 DO DO2019000099A patent/DOP2019000099A/es unknown
-
2021
- 2021-11-04 US US17/519,329 patent/US20230065629A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3706762A4 (fr) | N4-hydroxycytidine et dérivés et leurs utilisations anti-virales | |
| MA46472A (fr) | Hétéromultimères alk4:actriib et leurs utilisations | |
| MA53400A (fr) | Hétéromultimères alk7: actriib et leurs utilisations | |
| MA43821A (fr) | Pyrimidines et variantes de celles-ci, et leurs utilisations | |
| EP3694861A4 (fr) | Composés hétérocycliques et leurs utilisations | |
| EP3475295A4 (fr) | Nouveau transporteur de nucléoside triphosphate et ses utilisations | |
| EP3313530A4 (fr) | Dérivés de 4,6-pyrimidinylène et utilisations de ceux-ci | |
| MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| MA55044A (fr) | Hétéromultimères alk4:actriib et leurs utilisations | |
| EP3496757A4 (fr) | Antifolates de polyglutamates et leurs utilisations. | |
| EP3236972A4 (fr) | N4-hydroxycytidine, ses dérivés et utilisations anti-virales | |
| EP3624797A4 (fr) | Inhibiteurs de kinase et leurs utilisations | |
| EP3297637A4 (fr) | Dérivés de benzène-1,3,5-tricarboxamide et utilisations de ces dérivés | |
| MA44489A (fr) | Pyrimidines et variants de celles-ci, et leurs utilisations | |
| EP3559000A4 (fr) | Dérivés de benzimidazole, leurs procédés de préparation et leurs utilisations | |
| EP3325010A4 (fr) | Anticorps anti-facteur de coagulation xia et leurs utilisations | |
| EP3841096A4 (fr) | Dérivés de pyridinylméthylènepipéridine et leurs utilisations | |
| EP3323817A4 (fr) | Dérivés d'aniline pyrimidine et leurs utilisations | |
| MA50413A (fr) | Dérivés de benzimidazole et leurs utilisations | |
| EP3526215A4 (fr) | Dérivés de n-acyléthanolamide et leurs utilisations | |
| EP3347021A4 (fr) | Cyano-thiénotriazoloazépines et leurs utilisations | |
| MA46901A (fr) | Agents psychotropes et leurs utilisations | |
| EP3535243A4 (fr) | Dérivés hétérocycliques tricycliques et leurs utilisations | |
| EP3370771A4 (fr) | Conjugués anti-cd3-folate et leurs utilisations |